TNFRSF8 and anaplastic large cell lymphoma: In the first in human phase I dose escalation study, brentuximab vedotin was administered to 45 patients with relapsed or refractory CD30-positive lymphomas, primarily HL and anaplastic large cell lymphoma (ALCL) [257].